From "flights" to earning more miles. New perspectives on Cannabidiol (CBD) use.

A review, recently published in the Journal of Cannabis Research, focuses on the use of cannabidiol (CBD) for therapeutic purposes. Also examines the clinical evidence supporting its effectiveness in various conditions.

Currently, only one CBD product called Epidiolex is approved to treat seizures in specific syndromes.

This review highlights the areas where purified CBD has the most clinical evidence for its potential benefits.

These include:

Anxiety (positive data from 24 different studies)
Psychosis and schizophrenia (positive data from 9),
PTSD (positive data from 6), and
Substance abuse (positive data from 5 ).

Since the 1970s, researchers have studied how cannabidiol (CBD) affects anxiety and stress in both healthy volunteers and patient groups. Acute dosages of CBD have been shown in investigations involving healthy volunteers to lessen the anxiety that tetrahydrocannabinol (THC) administration causes.

CBD taken orally in a single dose was found effective in reducing anxiety related to public speaking. It also contributed to the extinction of traumatic memories.

According to functional brain imaging studies, CBD may have anxiolytic effects since it decreased brain activity in areas of the brain linked to fear and anxiety.

Both an acute and a seven-day oral CBD treatment in healthy males decreased resting blood pressure and blood pressure response to stress.

The most current research on healthy volunteers, however, did not find any measurable anxiolytic effects of CBD. It is important to note that most of the participants in these experiments were female, and new preclinical data show the anxiolytic effects of CBD may be stronger in male rats.

The effects of CBD on anxiety were examined in several trials. While some produced unfavorable findings, individuals with Parkinson’s disease, heroin use disorder, and generalized social anxiety disorder (SAD) all reported beneficial outcomes.

In these patients, CBD was found to reduce cravings, anxiety brought on by public speaking, negative assessment, cognitive impairment, and subjective anxiety.

In conclusion, there is conclusive evidence that a single dose of CBD can reduce blood pressure and anxiety in healthy volunteers.

CBD has shown promising preliminary in SAD patients and has produced mixed results in anxiety associated with substance abuse and other conditions.

Ongoing trials are investigating the effects of CBD in various conditions, such as SAD, pediatric epilepsy, advanced breast cancer, anorexia nervosa, bipolar disorder, and Alzheimer’s disease, which will contribute to the growing evidence base on the use of CBD for anxiety-related conditions.

The review notes, also, that there is limited evidence or lack of support for the use of purified oral CBD in pain management (especially as an acute analgesic), the treatment of COVID symptoms, cancer, Huntington’s disease, or type 2 diabetes.

As usual, to establish the efficacy of purified CBD in various indications, larger trials are needed.

Source
O’Sullivan, S.E., Jensen, S.S., Nikolajsen, G.N. et al. The therapeutic potential of purified cannabidiol. J Cannabis Res 5, 21 (2023). https://doi.org/10.1186/s42238-023-00186-9

Light Therapy holds promise as a treatment for Alzheimer's Disease

A new article, conducted by Lili Zang and colleagues from Weifang Medical University School of Nursing in Shandong Province, China, discusses a meta-analysis of 15 high-quality trials that investigated the impact of light therapy on individuals with Alzheimer’s disease (AD). The meta-analysis included 598 patients with mild to moderate Alzheimer’s disease, and it covered 15 randomized controlled trials conducted in seven different countries. Those trials were published between 2005 and 2022. Sleep Improvement Light therapy led to significant improvements in several sleep measures. It notably enhanced sleep efficiency, increased interdaily stability, and reduced intradaily variability, all of which are indicators of better sleep quality. Light therapy was associated with a reduction in agitation, depression, and caregiver burden among individuals with Alzheimer’s disease. A significant advantage over usual care was shown in reducing the severity of psychobehavioral symptoms, as assessed...

Los no fumadores engordan menos

Un nuevo estudio relaciona el tabaquismo con la ganancia de peso, y concluye que las personas fumadoras activas, no sólo las que lo dejan, engordan más que las no fumadoras. Después de cuatro años de análisis en la Universidad de Navarra, las personas que menos engordaron fueron las que nunca habían fumado.

Lacticaseibacillus rhamnosus may help in periodontal disease

A new study explores how a specific probiotic, Lacticaseibacillus rhamnosus GG (LGG), might help improve the regeneration of bones in the gums affected by periodontal disease, especially in the presence of high cholesterol levels (hyperlipidemia). Periodontal disease can lead to the loss of bone in the jaw, making it challenging for the bone to regenerate. The researchers used a rat model with conditions mimicking periodontal disease, high cholesterol, and a defect in the gums. The rats were given LGG for six weeks, and then various measurements were taken after sacrificing the rats to understand the effects. They found that the bone density, volume, and thickness in the affected area increased after the rats were given LGG. Interestingly, these improvements were not due to direct effects on the oral bacteria but were linked to changes in the gut microbiota. When fecal matter containing the altered gut bacteria from LGG-treated rats was transplanted into other rats, si...

Wellness-uptodate

Search This Blog